What's Happening?
Sera Prognostics, a health diagnostics company based in Salt Lake City, Utah, has announced the appointment of Mark Capone to its Board of Directors. Capone, a seasoned healthcare executive with over 40 years of experience, previously served as CEO of Myriad
Genetics. His expertise in diagnostics and life sciences is expected to aid Sera Prognostics in expanding the adoption of its PreTRM® Test, a blood-based biomarker test that predicts the risk of preterm birth. This appointment aligns with Sera's mission to improve maternal and neonatal health through precision pregnancy care.
Why It's Important?
The inclusion of Mark Capone on Sera Prognostics' board is significant as it brings valuable leadership and strategic insight to the company, particularly in the commercialization of complex diagnostic products. The PreTRM® Test addresses a critical need in maternal health by providing early risk assessment for preterm births, which are a leading cause of neonatal morbidity and mortality. Capone's experience is expected to enhance Sera's efforts in navigating the healthcare market and expanding the test's reach, potentially improving outcomes for mothers and newborns and reducing healthcare costs associated with preterm births.
